IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer June 10, 2026
US FDA Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic NSCLC June 10, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform June 10, 2026
Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer June 10, 2026
FDA accepts NDA for giredestrant in ER+ve early-stage breast cancer with positive Ph 3 results in the curative setting June 10, 2026
CytomX and Regeneron Expand Strategic Research Collaboration on Conditional Bispecific Therapeutics for Treating Cancer June 10, 2026
Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development June 10, 2026
Roche and Nurix Therapeutics to co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology June 10, 2026
Trial Discontinuation: External DMC recommends discontinuing Ph 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy + KEYTRUDA in 1L metastatic NSCLC with high PD-L1 expression June 10, 2026
Lancet Oncology publishes results of Pivotal Ph 3 Significant DFS Improvement with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer June 10, 2026
NEJM publishes results from ASCERTAIN-V Ph 1/2 trial of decitabine-cedazuridine + venetoclax in 1L AML patients ineligible for intensive induction chemo June 10, 2026
IBI343 (arcotatug tavatecan) Met Primary Endpoint in Ph 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA June 10, 2026
